Coeptis Therapeutics Stockholders to Vote on Share Increase

TL;DR

Coeptis Therapeutics holding shareholder vote to double authorized shares to 200M. Big deal for future funding.

AI Summary

On December 18, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing a special meeting of stockholders. The primary purpose of this meeting was to vote on a proposed amendment to the company's Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000.

Why It Matters

This vote is crucial for Coeptis Therapeutics as it will determine the company's ability to raise future capital through stock offerings, which is essential for its growth and development in the biotechnology sector.

Risk Assessment

Risk Level: medium — Increasing authorized shares can dilute existing shareholders if not managed carefully, but it's also necessary for future growth and funding.

Key Numbers

• 100,000,000 — Current Authorized Shares (Existing limit before proposed amendment.)
• 200,000,000 — Proposed Authorized Shares (Target number of shares after amendment, enabling future capital raises.)

Key Players & Entities

• Coeptis Therapeutics Holdings, Inc. (company) — Registrant
• 100,000,000 (dollar_amount) — Current authorized shares of common stock
• 200,000,000 (dollar_amount) — Proposed authorized shares of common stock
• December 18, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share COEP Nasdaq Capital Mark
• $11.50 — e-half of one share of Common Stock for $11.50 per whole share COEPW Nasdaq Capita
• $20.0 million — e vote to approve the issuance of up to $20.0 million of securities in connection with a Stan

Filing Documents

• coeptis_8k.htm (8-K) — 40KB
• 0001683168-24-008891.txt ( ) — 254KB
• coep-20241218.xsd (EX-101.SCH) — 3KB
• coep-20241218_def.xml (EX-101.DEF) — 26KB
• coep-20241218_lab.xml (EX-101.LAB) — 36KB
• coep-20241218_pre.xml (EX-101.PRE) — 25KB
• coeptis_8k_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders On December 18, 2024, Coeptis Therapeutics Holdings, Inc. (the "Company") held an Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on the proposals set forth below, which are each described in greater detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission ("SEC") on November 14, 2024 (the "Proxy or approximately 65.05%, were present virtually or represented by proxy at the Annual Meeting, and the 5,825 shares of Series A Preferred Stock outstanding and entitled to vote on an as-converted basis as of the record date, 4,100 shares, or approximately 70.39%, were present virtually or represented by proxy at the Annual Meeting. On a combined basis, approximately 65.89% of the eligible voting shares were present virtually or represented by proxy at the Annual Meeting. The final voting results for the matters submitted to a Company stockholder vote at the Annual Meeting are as follows: 1) At the Meeting, the vote to elect seven (7) directors, was as follows: FOR WITHHELD BROKER NON-VOTE David Mehalick 21,056,378 1,192,394 9,864,172 Daniel Yerace 21,055,405 1,193,367 9,864,172 Christopher Calise 21,178,292 1,070,480 9,864,172 Tara Maria DeSilva 21,058,324 1,190,448 9,864,172 Philippe Deschamps 21,056,999 1,191,773 9,864,172 Christopher Cochran 21,087,558 1,161,214 9,864,172 Gene Salkind 21,054,824 1,193,948 9,864,172 2) At the Meeting, the vote to ratify the appointment of Astra Audit & Advisory, LLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, was as follows: FOR AGAINST ABSTAIN 30,991,949 1,085,521 35,474 3) At the Meeting, the vote to approve an amendment to the

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Coeptis Therapeutics Holdings, Inc. Date: December 20, 2024 By: /s/ David Mehalick David Mehalick Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR